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ABSTRACT
Bacterial infections are becoming more difﬁcult to treat. At the present time c. 70% of nosocomial
infections are resistant to at least one antimicrobial drug that previously was effective for the causative
pathogen. Pathogens that are notorious for their virulence and ability to develop resistance include
Staphylococcus aureus, Enterococcus spp., members of the Enterobacteriaceae, Pseudomonas aeruginosa, and
Acinetobacter species. Notable resistance patterns that have emerged include methicillin resistance in
S. aureus, which started in the healthcare setting but has now moved into the community. Vancomycin
resistance in enterococci is frequently seen, and vancomycin resistance in methicillin-resistant S. aureus
is a public health threat. Resistance patterns seen in pseudomonal and Acinetobacter infections are
rapidly shifting. The situation has become sufﬁciently serious for clinical opinion leaders to call upon
governments for assistance in addressing the problem. In this worsening environment, in which patients
are at progressively greater risk of untreatable infections, clear recommendations for prescribers are
urgently needed. Severity of infection and underlying conditions are key issues, as patients with the
most serious diseases are those in most urgent need, and improvements in our ability to predict likely
infecting pathogens when empirical therapy is necessary are needed. Risk-factors and local resistance
patterns must be accounted for, and initial empirical therapy should be adequately broad spectrum and
adequately dosed. Agents must be highly active, able to penetrate adequately to the site of infection,
safe, and well-tolerated.
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INTRODUCTION
Although the phenomenon of drug resistance in
bacterial pathogens is not new, the high prevalence
of drug-resistant highly pathogenic bacteria has
been unprecedented in recent years. Data on
methicillin-resistant Staphylococcus aureus (MRSA),
a key contributor to concern about resistant patho-
gens, illustrate the scope of this problem. The
European Antimicrobial Resistance Surveillance
System (EARSS) reported in 2005 [1] on 30 coun-
tries that submitted results for MRSA. All of the
southern European countries reported high levels
of MRSA (eight with rates of over 40%). Four
countries (Czech Republic, Slovakia, Hungary and
Germany) with rates of MRSA below 10% in 2001
reported dramatic increases in 2005. Only seven
(mainly northern countries) reported MRSA rates
below 3%, although signiﬁcant increases were
reported for three of these: The Netherlands (from
0.34% – 0.93%), Denmark (0.28% – 1.7%), and
Finland (0.95% – 2.91%). The only exceptions to
this trend were France and Slovenia, both of which
succeeded in consistently reducing proportions of
methicillin-resistant isolates from 2001 to 2005. In
the USA, the continuing increase in levels of
staphylococcal resistance in hospitals remains a
cause for concern. The proportion of isolates of
S. aureus thatwere resistant tomethicillin, oxacillin
or nafcillin was reported as continuing to rise, and
in 2004 it had reached nearly 60%. Furthermore,
the hospital is not the only source of resistant
pathogens, as genetically distinct MRSA strains
have emerged in the community [2].
The challenge of antimicrobial resistance is not
limited to MRSA. Currently, the annual incidence
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of nosocomial infections due to any resistant
bacterial species in the USA is c. 1.4 million [3].
Severe infections caused by antimicrobial resis-
tance pose obvious treatment challenges. The aim
of this article is to review trends in MRSA and
other resistant pathogens associated with serious
infections, to discuss the characteristics of an
optimal antibiotic, and to consider strategies for
managing patients infected with resistant organ-
isms.
PATIENTS WITH SEVERE
INFECTIONS
Patients with severe infections have urgent treat-
ment needs; thus, severe infections must be
identiﬁed quickly. Severity of infection is deter-
mined by three factors: (i) host (patient) charac-
teristics, (ii) the disease or syndrome itself, and
(iii) the pathogen causing the illness (species,
virulence, and susceptibility to antimicrobial
agents).
Populations in developed countries are ageing,
and as a result, patients are increasingly elderly,
more debilitated, more likely to have underlying
medical conditions, and more likely to be immu-
nosuppressed because of ageing, disease, and ⁄ or
medical therapy. Increasing proportions of
patients have resistant infections from institutions
such as nursing homes and rehabilitation centres.
Readmissions related to short hospital stays may
introduce into the hospital environment large
numbers of patients who have been recently
treated with antibiotics [4–7].
Infectious disease syndromes that may imme-
diately be classiﬁed as severe infection include
those involving the central nervous system, bac-
teraemia ⁄ sepsis, hospital-acquired pneumonia,
and severe soft-tissue infections. Nosocomial
bloodstream infections are a major cause of death
and morbidity in the USA, with an estimated
quarter of a million cases annually [8]. Moreover,
the numbers of such infections caused by
antibiotic-resistant organisms are increasing in
the USA. The nationwide Surveillance and Con-
trol of Pathogens of Epidemiological Importance
(SCOPE) survey, carried out from 1995 to 2002 in
49 US hospitals recorded 24 179 nosocomial
bloodstream infections, 87% of which were
monomicrobial [9]. The proportion of S. aureus
species with methicillin resistance increased from
22% in 1995 to 57% in 2001. Over the course of
the survey, vancomycin resistance was seen in 2%
of Enterococcus faecalis and 60% of Enterococcus
faecium isolates.
PATHOGENS ASSOCIATED WITH
SERIOUS INFECTIONS
MRSA
Along with the high prevalence of hospital-
acquired MRSA in the USA and its increasing
prevalence in other countries, the emergence of
community-acquired MRSA infection is of public
health concern, particularly because of the risk of
transmission [10]. Community-acquired MRSA
infections are now being reported in young and
healthy individuals with no obvious risk-factors
[11–13]. Most cases involve skin and soft-tissue
infection, but life-threatening invasive infections
such as necrotising pneumonia [14], necrotising
fasciitis [15] and sepsis [16] are also being
reported. In some areas, community-acquired
MRSA infections have become more prevalent
than community-acquired infections with methi-
cillin-susceptible strains [10].
Characterisation of 117 community-acquired
MRSA isolates from the USA, France, Switzer-
land, Australia, New Zealand and Western Samoa
has identiﬁed genes that are unique to community-
acquired organisms and are shared by isolates
from all three continents (North America, Europe,
and Oceania) [17]. These are a type IV SCCmec
cassette (a methicillin resistance locus) and the
locus for Panton–Valentine leukocidin (PVL).
The PVL locus is carried on a bacteriophage and
appears to represent a stable marker of commu-
nity-acquired MRSA in different countries [17].
There appears to be an association between
MRSA and the presence of PVL in skin and
respiratory tract infections (Strauss et al., 47th
ICAAC, abstract K-1092; Strauss et al., 17th
European Congress of Clinical Microbiology and
Infectious Diseases, abstract O120). In a series of
415 skin and soft-tissue infections (abscesses,
wounds, or cellulitis) analysed for PVL expres-
sion, PVL-positive strains of MRSA (and methi-
cillin-sensitive S. aureus) were found to be widely
prevalent in deep-seated complicated skin and
skin structure infections (Strauss et al., 17th
European Congress of Clinical Microbiology
and Infectious Diseases, abstract O120). PVL
expression was signiﬁcantly more likely to be
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associated with abscess formation than with non-
abscess-forming deep infections (Fig. 1).
PVL positivity was found to be associated with
rapidly progressive, haemorrhagic, necrotising
pneumonia, a disorder that mainly affects other-
wise healthy children and young adults and that
involves high rates of mortality [18]. Of a series of
eight patients in France, six died after infection
with community-acquired pneumonia caused by
S. aureus carrying the PVL gene. Further analysis
of eight prospective and eight retrospective cases
of pneumonia caused by PVL-positive S. aureus
and 36 cases associated with PVL-negative
strains showed survival rates 48 h after hospital
admission of 63% and 94%, respectively (p 0.007)
[18].
Enterococci
Enterococci are normal inhabitants of the gastro-
intestinal tract but may also be associated with
infection [19]. In the SCOPE survey, 9% of the
causative pathogens in nosocomial bloodstream
infections were enterococci [9].
Most clinical laboratories report that 80%–90%
of enterococci are E. faecalis, and E. faecium
accounts for 5%–10% of isolates [20]. E. faecium
strains expressing high levels of resistance to
ampicillin emerged in the USA in the late 1980s
[21]; vancomycin-resistant Enterococcus (VRE) sub-
sequently appeared in 1989 [20]. Since that time,
the incidence of VRE has continued to increase,
and VRE now accounts for more than 25% of
enterococcal isolates in some intensive care
facilities [22]. A 10-year survey of enterococcal
isolates at a major medical centre in Chicago that
was carried out from 1993 to 2002 [23] showed a
signiﬁcant increase in the proportion of entero-
cocci identiﬁed as E. faecium from 12.7% – 22.2%
(p <0.001). The proportion of E. faecium isolates
that were resistant to vancomycin increased from
28.9% to 72.4% (p <0.001).
Pseudomonas aeruginosa
P. aeruginosa is a leading nosocomial pathogen
that is often associated with pneumonia, particu-
larly in the intensive care setting [24]. In addition
to pneumonia, P. aeruginosa may be associated
with bacteraemia, endocarditis, exacerbation of
cystic ﬁbrosis, keratitis and traumatic endoph-
thalmitis [25]. Neutropenic and mechanically
ventilated patients are at particular risk of pseud-
omonal infection, and mortality rates in infected
individuals exceed 30% [24]. The importance
and virulence of P. aeruginosa have been stressed,
with this organism remaining identiﬁable in
respiratory samples for as long as 48 h after
effective antimicrobial therapy has been initiated.
In addition, type III secretory proteins are recog-
nised as important virulence factors. The type III
secretion phenotype in P. aeruginosa has been
associated with worse outcomes in patients with
ventilator-associated pneumonia [24].
P. aeruginosa has high inherent resistance to
many drug classes, in part because of its semi-
permeable outer-membrane and possession of
efﬂux systems that reduce intracellular concen-
trations of antimicrobial agents. Alarmingly,
P. aeruginosa also frequently mutates during
courses of therapy. Current treatment options
are therefore limited and empirical treatments are
commonly inadequate [26,27]. P. aeruginosa iso-
lates are occasionally resistant to all antibiotics, a
problem that appears to be growing with the
emergence of integrins that carry gene cassettes
encoding both carbapenemases and amikacin
acetyltransferases [26].
Falling rates of susceptibility of P. aeruginosa
to available antibacterial agents have been docu-
mented (Fig. 2). Data from the Tracking Resis-
tance in the United States Today study, which
collected 2394 isolates from 2001 to 2003, showed
piperacillin–tazobactam, cefepimeandceftazidime
to be the most active agents against P. aeruginosa,
although susceptibility to any single agent tested
Fig. 1. Association between Panton–Valentine leukocidin
(PVL) gene expression in methicillin-resistant Staphylococ-
cus aureus (MRSA) isolates and type of skin and skin
structure infection in 415 S. aureus isolates analysed for
PVL (Strauss et al., 17th European Congress of Clinical
Microbiology and Infectious Diseases, abstract O120).
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was below 90% [28]. Susceptibility to cipro-
ﬂoxacin or levoﬂoxacin was c. 67%, and c. 9%
of isolates were multidrug-resistant. The preva-
lence of multidrug-resistant isolates increased
from 7.2% in 2001 to 9.9% in 2003.
Acinetobacter baumannii
A. baumannii is also emerging as a worldwide
cause of nosocomial infections. Acinetobacter spp.
were generally considered to be low-virulence
organisms that had been reported to increase in
virulence in critically ill or immunocompromised
patients [29]. Over the last decade, reports from
various parts of the world have suggested that
epidemic and more virulent strains of A. bauman-
nii are spreading in hospitals [30]. Disorders with
which this microorganism is associated include
pneumonia, bacteraemia, meningitis and urinary
tract and skin and soft-tissue infections. Isolates
resistant to nearly all commercially available
antimicrobial agents have been identiﬁed, and
treatment options for severe A. baumannii infec-
tions are becoming limited [31,32].
CURRENT TREATMENT OPTIONS
FOR MRSA
The agents most commonly used to treat MRSA
infections are glycopeptides. Vancomycin has
been the standard treatment and, until recently,
the only option for the management of patients
with MRSA [33]. Unfortunately, the efﬁcacy of
this group appears to be inferior to the b-lactams
and continues to diminish, with shifting MICs
and increasing emergence of vancomycin-inter-
mediate S. aureus and vancomycin-resistant
S. aureus [34–36]. The emergence of these strains
in addition to the spread of MRSA from the
hospital to community settings has become a
major cause of concern to clinicians and microbi-
ologists.
Teicoplanin is available as an alternative anti-
MRSA glycopeptide and has been suggested in
cases where patients cannot tolerate vancomycin
[37], but this agent has unpredictable pharmaco-
kinetics, and low dosages have been associated
with treatment failure [38]. Therapeutic drug
monitoring for teicoplanin has been advocated
but is not widely practised [38].
The novel cephalosporin ceftobiprole has
shown good activity against MRSA. Patients with
suspected MRSA-associated complicated skin
and skin structure infections were enrolled in a
double-blind, randomised study comparing cefto-
biprole 500 mg twice-daily with vancomycin 1 g
twice-daily in 15 countries (Strauss et al.,
44th Annual Meeting of IDSA, abstract 138).
Pathogens were isolated from 613 of 784 patients
enrolled. S. aureus was found in 494 baseline
samples, among which 190 ceftobiprole-treated
and 173 vancomycin-treated cases were evalu-
able. MRSA was isolated in 122 (21.8%) of
clinically evaluable patients, with clinical cure
rates (after 7–14 days) as shown in Table 1. MRSA
infections were especially prevalent in the USA;
cure rates with ceftobiprole exceeded 90% and
tended to be higher than US cure rates with
vancomycin. Ceftobiprole has also been shown
to have good activity against PVL-positive MRSA
and methicillin-susceptible S. aureus (Strauss
et al., 47th ICAAC, abstract K-1092).
Along with glycopeptides such as vancomycin
[33], current treatment options for MRSA include
oxazolidinones (linezolid) [39], daptomycin [40],
and the expanded-spectrum glycylcycline,
tigecycline [41]. Other potential treatments are
trimethoprim–sulfamethoxazole [42] and clinda-
mycin [43]. With the exception of tigecycline,
these agents have a relatively narrow spectrum of
activity, which frequently leads to the need for
combination therapy in the empirical setting.
Some currently available agents do not always
achieve the required penetration into target tis-
sues. Vancomycin has shown poor penetration
into the lungs in pharmacokinetic studies [44,45].
In addition, the drug has shown low cerebrospi-
nal ﬂuid penetration in infants undergoing shunt
Fig. 2. Multidrug resistance (‡3 drugs) among Pseudomo-
nas aeruginosa isolates tested with a panel of six antibiotics
in the USA, 1997–2000 [26]. Isolates were from over 250
hospitals participating in the Surveillance Network Data-
base USA.
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insertion [46], and suboptimal responses in
patients with bacteraemia and endocarditis have
been reported [47–49]. Daptomycin has shown
poor lung tissue penetration in animal studies, in
addition to inactivation by lung surfactant [50,51].
Systemic glycopeptides have also been recom-
mended for acute cancellous bone infections, but
vancomycin concentrations in cortical bone are
less satisfactory [38].
The toxicity proﬁle of current agents should
also be considered when selecting treatments for
patients with documented or suspected MRSA
infection. The nephrotoxicity and ototoxicity of
vancomycin is well-appreciated and can be a
particular problem at the aggressive doses used to
treat MRSA [52,53]. Using vancomycin in combi-
nation therapies to broaden the empirical spec-
trum has the potential to expose more patients to
the risk of these toxicities. Linezolid has been
investigated as an alternative to vancomycin and
other older agents in patients with multidrug-
resistant Gram-positive infections. While this
drug is generally well-tolerated, nearly 10% of
796 patients in a compassionate-use programme
experienced gastrointestinal disturbances, and
thrombocytopenia was seen in 7.4% of cases [39].
STRATEGIES FOR TREATING
TODAY’S SERIOUS INFECTIONS
The characteristics of an appropriate empirical
antimicrobial therapy are described in the article
by Chastre in this issue [54]. An ideal initial
antibiotic should be effective against a broad
range of pathogens, including resistant organ-
isms, highly active at the site of infection (with
mechanistic, pharmacokinetic and pharmacody-
namic characteristics consistent with this require-
ment), safe and non-toxic with few adverse
effects, and convenient to use.
The issue of range of coverage is often used as a
rationale for the initial empirical use of combina-
tion therapy in serious infections, with the com-
bination being switched to monotherapy once
culture data become available (de-escalation or
step-down therapy). The rationale for the empir-
ical use of combination antibiotics for proven or
suspected bacterial infections is to ensure initial
broad-spectrum coverage. Subsequently, once
culture data are available, the treatment regimen
could be de-escalated to focused monotherapy in
which the switch agent is microbiologically
appropriate for the infecting pathogen. The
debate about combination therapy is ongoing,
but the issue has been analysed in detail by Safdar
et al. [55], who carried out a meta-analysis of 17
studies (of which ﬁve were prospective cohort
studies and two were prospective, randomised
trials) in patients with Gram-negative bactera-
emia. Most studies used b-lactams or aminogly-
cosides alone and in combination. The pooled
odds ratio of 0.96 indicated no beneﬁt in terms of
mortality rate for combination therapy, although
the study did not assess other outcomes, such as
microbiological cure and emergence of resistance.
The general applicability of the ﬁnding is uncer-
tain, as 11 of the 17 studies focused on a particular
organism (ﬁve studies were on P. aeruginosa and
four on Klebsiella spp.). In addition, there was
considerable heterogeneity among studies, reﬂect-
ing the widely varying study designs, different
organisms analysed and antibiotics studied. The
fact that many of the studies were observational
also means that confounding factors (e.g., severity
of illness; underlying disease) cannot be ruled
out. Further study will be required to clarify the
beneﬁt of combination therapy.
The evidence shows that failure to initially treat
high-risk microbiologically documented infec-
tions appropriately is associated with increased
rates of mortality and morbidity [56]. Risk strat-
iﬁcation should therefore be employed to identify
patients at high risk of infection with resistant
strains of bacteria (e.g., patients with prior anti-
biotic treatment during hospitalisation, prolonged
stay in hospital and invasive devices); indeed, this
Table 1. Staphylococcal infections
and cure rates in patients with com-
plicated skin and skin structure
infections treated with ceftobiprole
500 mg twice-daily or vancomycin
1 g twice-daily (Strauss et al., 44th
Annual Meeting of IDSA, abstract
138)
Population
All
Staphylococcus aureus
Methicillin-resistant
Staphylococcus aureus
Ceftobiprole Vancomycin Ceftobiprole Vancomycin
USA 92.9% (52 ⁄ 56) 85.5% (53 ⁄ 62) 92.7% (38 ⁄ 41) 85.0% (34 ⁄ 40)
All countries 94.7% (180 ⁄ 190) 94.2% (163 ⁄ 173) 91.9% (57 ⁄ 62) 90.0% (54 ⁄ 60)
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approach may be considered to be pre-emptive.
Expert opinion in the USA suggests that such
high-risk patients should be treated with combi-
nation therapy designed to cover most pathogens
likely to be implicated in any infection in the
setting in question, with de-escalation being
thought of as a strategy to balance the need for
appropriate initial therapy with the avoidance of
unnecessary antibiotic utilisation [56].
When prescribing antimicrobial therapy for
patients with infections, the clinician must take
commonly encountered resistant organisms into
account. Risk-factors for MRSA that prescribers
must be alert to include those common to all
S. aureus infections such as skin pathology (e.g.,
wounds or dermatitis) and needle use (as in
patients with diabetes, those needing dialysis,
and those with intravenous catheters). Those
speciﬁc to MRSA include prolonged hospitalisa-
tion, contact with healthcare institutions, proxim-
ity to an MRSA carrier, and prior treatment with
certain antibiotics [57–60]. A case-control study
carried out in 121 patients with MRSA and 123
patients with methicillin-susceptible S. aureus
showed factors independently associated with
MRSA infection to be previous hospitalisation,
longer length of stay before infection, previous
surgery, enteral feeding, macrolide use and lev-
oﬂoxacin use [61].
The epidemiology of MRSA and especially
community-acquired MRSA is evolving rapidly.
Previously, risk-factors for MRSA in the commu-
nity were well-deﬁned and included a history of
prolonged hospitalisation, prior admission to a
nursing home or other long-term care facility,
and injectable drug use [57–59]. But community-
acquired MRSA infections are now being reported
in speciﬁc populations of young and healthy
individuals associated with no obvious risk
factors, such as professional football players
and children [11–13]. Other speciﬁc populations
that have been identiﬁed as being at risk for
community-acquired MRSA from other studies
include injection drug users, those with prior
endocarditis, those with hospitalisation within
the previous year, sports participants, incarcer-
ated persons, military recruits, and a number of
distinct ethnic populations, including Alaskan
natives, Native Americans, and Paciﬁc Islanders
[57,59].
Findings from the Minnesota Department of
Health provide an important perspective on the
risk of community-acquired MRSA infection. A
prospective study analysed all MRSA infections
identiﬁed in 2000 at 12 laboratories in a sentinel
surveillance network [60]. Of 1100 infections, 131
(12%) were community-acquired MRSA infec-
tions. Skin and soft-tissue infections were more
common in community-associated infections than
in those associated with healthcare settings, and
most cases of community-acquired MRSA were
initially treated with antibiotics to which they
were not susceptible. Notably, the Minnesota
laboratories also found that community-acquired
MRSA isolates had distinct exotoxin genes (e.g.,
PVL) and antimicrobial susceptibility proﬁles
(Table 2). These ﬁndings suggest strongly that
any person presenting to a hospital emergency
room with a skin or skin structure infection in the
USA should be suspected of having community-
acquired MRSA.
Community-acquired MRSA may be a common
cause of bacteraemia. A study by Huang et al. of
antimicrobial resistance in hospitals in San Fran-
cisco County from 1996 through 1999 showed
high rates of MRSA bacteraemia detected at
admission and during the ﬁrst day of hospitali-
sation; these rates were as high or higher than
those detected upon or 2 weeks after admission
(Fig. 3), which would presumably be nosocomial
infections [62].
Table 2. Antimicrobial susceptibility of community-asso-
ciated and healthcare-associated methicillin-resistant
Staphylococcus aureus isolates in Minnesota for the year
2000. Adapted with permission [60]. Drugs showing
statistically signiﬁcant differences (p £0.001) between com-
munity- and healthcare-associated isolates are highlighted
in bold
Antibiotic
Percentage of isolates
susceptible
Community-
associated
(n = 106)
Healthcare-
associated
(n = 211)
Methicillin 0 0
Ciproﬂoxacin 79 16
Clindamycin 83 21
Erythromycin 44 9
Gentamicin 94 80
Rifampicin 96 94
Tetracycline 92 92
Trimethoprim–
sulfamethoxazole
95 90
Vancomycin 100 100
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MRSA infection may be predictable at the
individual patient level on the basis of endemic
status. Two studies in patients with skin and soft-
tissue infections carried out in 2003 in the USA
and Canada encouraged inclusion of persons with
MRSA. The respective proportions of patients
with MRSA were 65% and 79%, with physicians’
predictions of this type of infection having a
positive predictive value of 68%. The most com-
mon reasons for suspecting MRSA were high
prevalence in the community (67%) and prior
MRSA infection (23%). In a further study in
which suspected MRSA constituted grounds for
exclusion, the proportion of MRSA infections was
reported to be 46%, with a physicians’ negative
predictive value of 64% by (Carmeli et al., 45th
ICAAC, abstract L-1574).
The dynamic epidemiological picture of S. aur-
eus and MRSA requires healthcare providers to be
constantly aware of current epidemiological
trends, which include local and regional patterns
and global migration of speciﬁc strains [63].
Consequences of treatment delay
Inappropriate or delayed treatment in patients
with severe infections has serious implications for
patient outcomes. The classic 1985 study by
Bodey et al. was a retrospective review of 410
cases of Pseudomonas bacteraemia in patients with
cancer that illustrates this point [64]. Pseudomonas
bacteraemia was most common among patients
with acute leukaemia; most patients had acquired
their infections in hospital, and 51% had received
antibiotics for other infections during the preced-
ing week. Shock was documented in 33% of
patients, and 32% had concomitant pneumonia.
The overall cure rate was 62%. The importance of
appropriate therapy was apparent: a cure rate of
67% was noted in patients who received appro-
priate antibiotics, but this dropped to only 14% in
those who did not receive appropriate antimicro-
bial therapy. Moreover, a 1- to 2-day delay in the
administration of appropriate antibiotic therapy
reduced the cure rate from 74% – 46%. Patients
who received an anti-pseudomonal b-lactam,
with or without an aminoglycoside, had signiﬁ-
cantly higher cure rates than those who received
an aminoglycoside only (72% and 71% vs. 29%).
More recent studies of the detrimental effects of
delay of appropriate antimicrobial treatment are
reviewed in the articles by Davey and Chastre in
this issue [54,65]. These studies show that treat-
ment delay leads to treatment failure and to
increases in rates of morbidity and mortality and
thus must be avoided.
ADDITIONAL STRATEGIC ISSUES
A need to improve physician awareness of the
effect of prompt and effective diagnosis on the
likelihood of successful therapy when using
antibiotics in an environment in which drug-
resistant microorganisms are becoming more
prevalent is apparent. As highlighted earlier in
the present review, appropriate and adequate
therapy at the earliest opportunity avoids treat-
ment delay and dramatically increases the prob-
ability of successful eradication of infection.
Appropriate sample cultures are needed as soon
as possible in order to inform treatment decisions
after initial empirical therapy. Indeed, times to
diagnosis must be shortened; in particular, faster
delivery of samples to laboratories, more rapid
processing times and quicker reporting are all
simple means by which delivery of effective
treatment can be hastened.
Some individualisation of treatment decisions
is also required. Formulaic treatment plans
(where an infection type is directed towards a
ﬁxed treatment type) may be over-simplistic
and may not provide solutions in this complex
setting. Severity of infection must be considered,
together with likely infecting pathogens (based
on identiﬁable risk-factors as discussed earlier)
and what is known about local resistance
Fig. 3. Methicillin-resistant Staphylococcus aureus (MRSA)
and vancomycin-resistant Enterococcus (VRE) isolates
obtained from blood samples by hospital day of admission
from a study of San Francisco County hospitals from 1996
to 1999. Reproduced with permission [62].
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patterns. Adoption of de-escalation therapy
allows clinicians to initiate therapy with a
broad-spectrum antibiotic and follow with
focused treatment once culture data become
available. If implemented successfully, these
measures would be expected to improve patient
outcomes by decreasing rates of mortality,
preventing organ dysfunction, decreasing length
of stay, decreasing costs, and possibly reducing
overall antibiotic pressure. Use of escalation
therapy, whereby treatments are ‘stepped up’,
is likely to delay the use of appropriate and
adequate treatment, the principles of which
involve the use of highly active agents, achieve-
ment of appropriate levels of antibacterial agent
at the infection site, and use of agents known to
act effectively at the target site without risk of
inactivation or premature elimination.
CONCLUSION
Resistant, virulent pathogens have emerged over
the last decades in healthcare settings and in the
community, in many parts of the world; some
resistant species, such as MRSA, have reached
endemic levels. The prevalence of these patho-
gens, changes in healthcare settings, new ﬁndings
on the mechanisms of development of resistance
and the availability of new antimicrobial agents
call for adaptation of treatment strategies to
improve patients’ outcomes.
Antibiotic selection pressure should be mini-
mised without compromising patients’ outcomes.
Thus, choice of empirical therapy should be
individualised and take into consideration the
clinical syndrome, the affected patient’s medical
history, the suspected organisms, and the severity
of the infection. The patient’s risk of infection
with a resistant organism should be considered
on the basis of past exposures, co-morbid condi-
tions, and the local epidemiology. Decisions
regarding antimicrobial therapy should also take
into account safety and tolerability.
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